A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases.
Acta Oncol
; 51(5): 584-8, 2012 May.
Article
em En
| MEDLINE
| ID: mdl-22248089
ABSTRACT
BACKGROUND:
To investigate the utility of stereotactic body radiotherapy (SBRT) in the treatment of painful renal cell carcinoma (RCC) bone metastases, and for a possible dose effect on time to symptom relief. MATERIAL ANDMETHODS:
Eighteen patients with 24 painful osseous lesions from metastatic RCC were treated with SBRT. The most common treatment regimens were 24 Gy in 3 fractions and 40 Gy in 5 fractions. The times from treatment to first reported pain relief and time to symptom recurrence were evaluated. Median follow-up was 38 weeks (1-156 weeks).RESULTS:
Seventy-eight percent of all patients had pain relief. Patients treated with a BED > 85 Gy achieved faster and more durable pain relief compared to those treated with a BED < 85 Gy. There was decrease in time to pain relief after a change in treatment regimen to 8 Gy × 5 fractions (BED = 86). There was only one patient with grade 1 skin toxicity. No neurological or other toxicity was observed.CONCLUSIONS:
SBRT can safely and effectively treat painful RCC bony metastases. There appears to be a relationship between radiation dose and time to stable pain relief.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dor
/
Neoplasias Ósseas
/
Carcinoma de Células Renais
/
Radiocirurgia
/
Neoplasias Renais
/
Recidiva Local de Neoplasia
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article